Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Polycystic Kidney, Autosomal Dominant

• Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
• A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
• A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
• Treatment of Vascular Stiffness in ADPKD
• Open-label, Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
• PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
• Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects
• Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
• Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
• Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
• Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
• Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
• Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
• Effect of Venglustat in Patients With Renal Impairment
• Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
• Tolvaptan-Octreotide LAR Combination in ADPKD
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
• The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
• Statin Therapy in Patients With Early Stage ADPKD
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
• Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
• Feasibility Study of Metformin Therapy in ADPKD
• Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
• Efficacy of Tolvaptan on ADPKD Patients
• Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
• Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
• Effect of the Aquaretic Tolvaptan on Nitric Oxide System
• Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
• Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
• Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
• Lanreotide In Polycystic Kidney Disease Study
• Effects of Somatostatin on Liver in ADPKD
• Effects of Somatostatin on ADPKD Heart
• Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
• Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
• Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
• Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Pasireotide LAR in Severe Polycystic Liver Disease
• Study of Lanreotide to Treat Polycystic Kidney Disease
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
• 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
• Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
• Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
• Bosutinib For Autosomal Dominant Polycystic Kidney Disease
• Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
• Tolvaptan Extension Study in Participants With ADPKD
• Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
• Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
• Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease
• Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease
• Lanreotide as Treatment of Polycystic Livers
• CCB Safety Study in Treatment of Hypertension of ADPKD
• Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
• Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Octreotide in Severe Polycystic Liver Disease
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
• Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study
• Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• HALT Progression of Polycystic Kidney Disease Study B